Lightpoint Medical, an innovative medical device company specializing in imaging technologies announced today that it has received an R01 grant of $2.6M million from the US National Cancer Institute. The funding will support clinical trials of Lightpoint’s EnLightTM molecular imaging technology in lymph node cancer and a range of gynecologic cancers at Memorial Sloan Kettering Cancer Center (MSK).
“Lightpoint is honored to receive this grant,” said Dr David Tuch, Lightpoint Founder and CEO. “We look forward to undertaking clinical trials to demonstrate the efficacy for EnLightTM for intraoperative cancer detection.”
Read more: PR Newswire